Oncology

Taking Cancer on

At Boehringer Ingelheim, we believe this can be the generation that redefines many cancers as curable diseases. We want to be part of this transformation.

Optimising outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

Document ID: PC-TH-100289

01/12/2018

Author: Dr Nicolas Girard

Treatment sequences in EGFR-mutant NSCLC after 1^st-line EGFR TKI

123,000
Views

100k 340

PC-TH-100291
Production date: Dec 2018

Oncology

Oncology

Optimising outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

eLearning

in BoehringerOne